MTND2P6

Across TCGA pan-cancer cohorts, MTND2P6 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTND2P6 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTND2P6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTND2P6 expression acts as an unfavorable survival marker.

MESO, DLBC, and COAD are the cancer types where MTND2P6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.144	0.557	.029	45	view →
DLBC	OS	Tertile	III,IV	0.175	0.874	.025	36	view →
COAD	OS	Tertile	IV	0.039	0.660	<.001	27	view →
STAD	OS	Quartile	II,III,IV	0.437	0.589	.005	18	view →
GBM	OS	Tertile	All	0.225	0.428	.003	18	view →
LUAD	OS	Tertile	IV	0.114	0.560	.038	18	view →
HNSC	DFS	Tertile	All	0.187	0.555	.036	9	view →
OV	OS	Quartile	II,III,IV	0.782	0.860	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTND2P6–MESO (OS)

Open the MESO breakdown →